DK1284720T3 - L-FMAU til behandling af hepatitis delta-virusinfektion - Google Patents
L-FMAU til behandling af hepatitis delta-virusinfektionInfo
- Publication number
- DK1284720T3 DK1284720T3 DK01922803T DK01922803T DK1284720T3 DK 1284720 T3 DK1284720 T3 DK 1284720T3 DK 01922803 T DK01922803 T DK 01922803T DK 01922803 T DK01922803 T DK 01922803T DK 1284720 T3 DK1284720 T3 DK 1284720T3
- Authority
- DK
- Denmark
- Prior art keywords
- fmau
- treatment
- hepatitis delta
- virus infection
- delta virus
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5765—Hepatitis delta antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19313500P | 2000-03-29 | 2000-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1284720T3 true DK1284720T3 (da) | 2007-01-15 |
Family
ID=22712393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01922803T DK1284720T3 (da) | 2000-03-29 | 2001-03-29 | L-FMAU til behandling af hepatitis delta-virusinfektion |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6670342B2 (da) |
| EP (1) | EP1284720B1 (da) |
| JP (1) | JP2003528138A (da) |
| KR (3) | KR100893549B1 (da) |
| CN (1) | CN1268345C (da) |
| AT (1) | ATE339211T1 (da) |
| AU (1) | AU2001249564A1 (da) |
| BR (1) | BR0109716A (da) |
| CA (1) | CA2405502A1 (da) |
| CY (1) | CY1105768T1 (da) |
| DE (1) | DE60123042T2 (da) |
| DK (1) | DK1284720T3 (da) |
| ES (1) | ES2272460T3 (da) |
| IL (1) | IL151981A0 (da) |
| PT (1) | PT1284720E (da) |
| WO (1) | WO2001072294A2 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE339211T1 (de) | 2000-03-29 | 2006-10-15 | Univ Georgetown | L-fmau zur behandlung von hepatitis-delta-virus- infizierung |
| US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
| DE10346721A1 (de) * | 2003-10-08 | 2005-05-04 | Holger Kalthoff | Oligonukleotide, diese enthaltende Mittel und deren Verwendung |
| WO2010090723A2 (en) * | 2009-02-04 | 2010-08-12 | University Of Georgia Research Foundation, Inc. | Methods of inhibiting fibrogenesis and treating fibrotic disease |
| JP5779799B2 (ja) * | 2009-11-16 | 2015-09-16 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド | ２’−フルオロ−６’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法 |
| US8816074B2 (en) | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
| MX361522B (es) * | 2012-08-30 | 2018-12-10 | Replicor Inc | Uso de agentes farmacéuticos para la preparacion de un medicamento para el tratamiento de hepatitis b y hepatitis d. |
| EA039949B1 (ru) * | 2012-09-21 | 2022-03-31 | Репликор Инк. | Способы лечения инфекций вирусом гепатита в и гепатита d |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| JP2017536403A (ja) * | 2014-12-04 | 2017-12-07 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | デルタ肝炎ウイルス感染の治療 |
| CN104694544A (zh) * | 2015-03-24 | 2015-06-10 | 刘红卫 | 结合丁型肝炎病毒的核酸适配子及其应用 |
| JP2018512428A (ja) * | 2015-04-07 | 2018-05-17 | スプリング バンク ファーマシューティカルズ，インコーポレイテッド | Ｈｂｖ感染の処置のための組成物および方法 |
| ES2844848T3 (es) | 2015-04-21 | 2021-07-22 | Eiger Biopharmaceuticals Inc | Composiciones farmacéuticas que comprenden Lonafarnib y Ritonavir |
| WO2017132332A1 (en) * | 2016-01-28 | 2017-08-03 | Svenska Vaccinfabriken Produktion Ab | Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes |
| CN106333960A (zh) * | 2016-11-01 | 2017-01-18 | 侯建生 | 臭氧化油在肝病防治中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US4093714A (en) | 1974-03-15 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 9β-D-Arabinofuranosylpurine nucleotides and method of use |
| US4210638A (en) | 1978-03-17 | 1980-07-01 | Pcr, Inc. | Antiviral composition and method of treating virus diseases |
| GB2060604B (en) | 1979-10-03 | 1983-11-23 | Univ Birmingham And Stichting | E15-(2-halogenovinyl)-2'-deoxycytidines |
| US4468384A (en) | 1982-01-05 | 1984-08-28 | The Research Foundation Of State University Of New York | Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| DE3479158D1 (en) | 1983-03-04 | 1989-08-31 | Noctech Ltd | Diagnostic agent, a process for its preparation and its use in diagnostic methods |
| US4666892A (en) | 1984-03-06 | 1987-05-19 | Sloan-Kettering Memorial Cancer Center | Method and composition for hepatitis treatment with pyrimidine nucleoside compounds |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| EP0251575B2 (en) | 1986-06-17 | 2002-11-13 | Chiron Corporation | Hepatitis delta diagnostics and vaccines, their preparation and use |
| US5246924A (en) * | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
| JPH03501253A (ja) | 1987-09-22 | 1991-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質 |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| JPH05507279A (ja) | 1990-05-29 | 1993-10-21 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | グリセロールジ―およびトリホスフェート誘導体の合成 |
| DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
| US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
| US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
| US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| EP0491077A1 (en) | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
| GB9110874D0 (en) | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
| EP0594677A4 (en) | 1991-07-12 | 1997-09-17 | Vical Inc | Antiviral liponucleosides: treatment of hepatitis b |
| US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| GB9116601D0 (en) | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
| AU701574B2 (en) | 1993-05-12 | 1999-02-04 | Karl Y. Hostetler | Acyclovir derivatives for topical use |
| DE69431596D1 (de) | 1993-06-10 | 2002-11-28 | Wake Forest University Winston | (phospho)lipide zum bekämpfen einer hepatitis b-infektion |
| US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| US5639647A (en) | 1994-03-29 | 1997-06-17 | Ribozyme Pharmaceuticals, Inc. | 2'-deoxy-2'alkylnucleotide containing nucleic acid |
| US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
| US5808040A (en) | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
| GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| WO1997031641A1 (en) * | 1996-02-29 | 1997-09-04 | Duke University | Method of treating hepatitis delta virus infection |
| US5753789A (en) | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
| DE19641034A1 (de) | 1996-10-04 | 1998-04-09 | Claussen Nils | Pulverförmige Zubereitung von wasserempfindlichen anorganischen Substanzen, ihre Herstellung und Verwendung |
| ATE339211T1 (de) | 2000-03-29 | 2006-10-15 | Univ Georgetown | L-fmau zur behandlung von hepatitis-delta-virus- infizierung |
| US6985662B2 (en) * | 2003-10-30 | 2006-01-10 | Corning Incorporated | Dispersion compensating fiber for moderate dispersion NZDSF and transmission system utilizing same |
-
2001
- 2001-03-29 AT AT01922803T patent/ATE339211T1/de not_active IP Right Cessation
- 2001-03-29 CA CA002405502A patent/CA2405502A1/en not_active Abandoned
- 2001-03-29 CN CNB018104134A patent/CN1268345C/zh not_active Expired - Fee Related
- 2001-03-29 IL IL15198101A patent/IL151981A0/xx unknown
- 2001-03-29 ES ES01922803T patent/ES2272460T3/es not_active Expired - Lifetime
- 2001-03-29 KR KR1020027012957A patent/KR100893549B1/ko not_active IP Right Cessation
- 2001-03-29 DE DE60123042T patent/DE60123042T2/de not_active Expired - Lifetime
- 2001-03-29 WO PCT/US2001/009987 patent/WO2001072294A2/en active IP Right Grant
- 2001-03-29 KR KR1020087014186A patent/KR20080059679A/ko not_active Application Discontinuation
- 2001-03-29 PT PT01922803T patent/PT1284720E/pt unknown
- 2001-03-29 DK DK01922803T patent/DK1284720T3/da active
- 2001-03-29 BR BR0109716-4A patent/BR0109716A/pt not_active Application Discontinuation
- 2001-03-29 JP JP2001570255A patent/JP2003528138A/ja not_active Withdrawn
- 2001-03-29 US US09/821,278 patent/US6670342B2/en not_active Expired - Lifetime
- 2001-03-29 AU AU2001249564A patent/AU2001249564A1/en not_active Abandoned
- 2001-03-29 KR KR1020087030736A patent/KR20090006230A/ko not_active Application Discontinuation
- 2001-03-29 EP EP01922803A patent/EP1284720B1/en not_active Expired - Lifetime
-
2002
- 2002-11-22 US US10/302,814 patent/US7511027B2/en not_active Expired - Fee Related
-
2006
- 2006-11-09 CY CY20061101613T patent/CY1105768T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20030158149A1 (en) | 2003-08-21 |
| CA2405502A1 (en) | 2001-10-04 |
| IL151981A0 (en) | 2003-04-10 |
| KR20090006230A (ko) | 2009-01-14 |
| KR100893549B1 (ko) | 2009-04-17 |
| JP2003528138A (ja) | 2003-09-24 |
| DE60123042T2 (de) | 2007-04-12 |
| ATE339211T1 (de) | 2006-10-15 |
| AU2001249564A1 (en) | 2001-10-08 |
| PT1284720E (pt) | 2006-12-29 |
| US7511027B2 (en) | 2009-03-31 |
| BR0109716A (pt) | 2003-06-17 |
| CN1268345C (zh) | 2006-08-09 |
| KR20030031472A (ko) | 2003-04-21 |
| KR20080059679A (ko) | 2008-06-30 |
| US20020160980A1 (en) | 2002-10-31 |
| US6670342B2 (en) | 2003-12-30 |
| EP1284720A2 (en) | 2003-02-26 |
| WO2001072294A2 (en) | 2001-10-04 |
| ES2272460T3 (es) | 2007-05-01 |
| DE60123042D1 (de) | 2006-10-26 |
| CY1105768T1 (el) | 2011-02-02 |
| CN1431907A (zh) | 2003-07-23 |
| EP1284720B1 (en) | 2006-09-13 |
| WO2001072294A3 (en) | 2002-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105768T1 (el) | L-fmau για την αντιμετωπιση μολυνσης απο ιο της ηπατιτιδας δελτα | |
| EA200201263A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ | |
| EA200201279A1 (ru) | Способы и композиции для лечения вирусного гепатита c | |
| YU94802A (sh) | 3-prolekovi 2'-deoksi-beta-l-nukleozida | |
| EE05442B1 (et) | Vikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks | |
| WO2003026589A3 (en) | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides | |
| DK1658302T3 (da) | Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C | |
| WO2001060315A3 (en) | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | |
| DK1115420T3 (da) | Behandling af hepatitis B med thymosin-alpha-1 og lamivudin | |
| RS20120367A2 (en) | METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C |